Dexamethesone
Preclinical
Dexamethesone is one of 11 therapeutic programs targeting Newly Diagnosed Multiple Myeloma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
11 competitors in Newly Diagnosed Multiple Myeloma
#DrugCompanyPhaseTrials
1Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Decadron
AAspen Global Incorporated
Approved
Kyprolis
VVirionyx Corporation Limited
Approved
Fludara
SanofiPhase 3
Darzalex
Johnson & JohnsonPhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
AZD0120
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Dexamethesone. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- DDana-Farber Cancer Institute